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CHAPTER 1
Pharmacoepidemiology
and the Elderly
S. Andrade and J. Gurwitz
Introduction
Pharmacoepidemiology employs the methods of epidemiology to
study the frequency, determinants, and outcomes of drug therapy.
Types of pharmacoepidemiologic investigations involve the
evaluation of:
• Adverse and beneficial drug effects;
• Medication utilization patterns;
• Drug effects on quality-of-life;
• Economic impacts of medication use.
Pharmacoepidemiology is becoming increasingly important
with the aging of Western populations, due to the increased
prevalence of medication use among older persons. In such
patients, the evaluation of the adverse consequences of using
multiple medications concomitantly is particularly important.
Types of Pharmacoepidemiologic Studies
Types of investigations encompassed within the discipline of
pharmacoepidemiology include the evaluation of adverse and
beneficial effects of drug therapies, medication utilization patterns,
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drug effects on the quality of life, and the economic impact of
medication use.
Adverse and Beneficial Effects of Drug Therapy
Pharmacoepidemiologic methods are most commonly employed
to study adverse drug effects using postmarketing surveillance
data. Some notable examples include the associations between
nonsteroidal anti-inflammatory drugs and serious gastrointestinal
complications such as haemorrhage and perforation,1–8 non-
steroidal anti-inflammatory drugs and nephrotoxicity,9,10 benzo-
diazepines and falls and hip fracture,11–13 and metoclopramide
and parkinsonism.14 In addition to quantifying the association
between a drug and a specific adverse effect, the interaction
between these effects and the demographic characteristics (gender,
age and race) of the patient, as well as the influence of comorbidity
and concomitant drug use can be evaluated.15
Pharmacoepidemiologic studies have also been used to evaluate
the beneficial effects of drug therapy, such as the protective
effects of aspirin use16,17 or estrogen replacement therapy18–20
against the occurrence of coronary heart disease, and the benefits
of inhaled steroids for preventing hospitalization for asthma.21
Drug Utilization Studies
Drug utilization studies are used to evaluate the frequency and
appropriateness of drug therapy. Patterns of medication use may
be determined over time in specific patient groups.
The data may be used to detect over- or under-utilization
of medications or to examine drug distribution or expenditure
issues.22  In addition, appropriateness of therapy may be evaluated
according to factors such as indication, dose, specific patient
characteristics, medical conditions, or concomitant drug use. Three
examples of drug utilization studies with special relevance to the
DRUGS AND THE OLDER POPULATION 
© Imperial College Press
http://www.worldscibooks.com/medsci/p085.html
PHARMACOEPIDEMIOLOGY AND THE ELDERLY 3
geriatric population are: (1) antipyschotic drug use in the nursing
home setting to treat agitation in patients with dementia, (2) the
use of thrombolytic therapy in elderly persons who suffer acute
myocardial infarction; and (3) the use of opioid analgesics in the
management of cancer pain.
Antipsychotic Drugs
For decades, the use of antipsychotic drugs has remained extensive
in nursing homes in the United States. Although recent regulatory
changes may have had some effect, antipsychotic drugs were,
until recently, given to about one fourth of all U.S. nursing home
residents.23 A few studies suggest that antipyschotic drugs may
be effective in the treatment of agitation in geriatric patients with
dementia,24 but the literature on this topic is both limited and
ambiguous. Clear evidence, however, links the use of these drugs
with extrapyramidal symptoms, gait instability, falls, and hip
fractures.25–27
Thrombolysis in Acute Myocardial Infarction
While the possibility of disabling or fatal intracranial haemorrhage
is always a concern in patients treated with thrombolytics, these
risks must be balanced against the benefits in the management
of elderly acute myocardial infarction patients. The risk of
death after acute myocardial infarction increases sharply with
advancing patient age, and the few trials that enrolled meaningful
numbers of elderly patients have suggested a beneficial effect of
thrombolysis on short-term mortality associated with acute
myocardial infarction in this population.28 Although there is a
larger proportionate reduction in mortality with thrombolytic
treatment for younger patients, older patients are at higher
absolute risk of dying from acute myocardial infarction. As a
result, the absolute mortality reductions (net lives saved per
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1,000 patients treated) are similar for younger and older patients.29
The view now is that age itself should not be a factor when
deciding whether or not to use thrombolytic therapy in the
setting of acute myocardial infarction.30 Yet, the use of these
agents in acute myocardial infarction declines considerably with
advancing patient age.31
Opioids for Pain Management in Cancer
Despite guidelines for pain management in metastatic cancer,32
treatment is often inadequate. In a study of 1,308 outpatients
with metastatic cancer being followed by oncologists, 769 patients
reported experiencing pain, which 62% characterized as
substantial.33 Patients with poor pain control reported that the
pain interfered with function and their quality of life. Older age
was an independent risk factor for inadequate pain management.
Concerns have been raised that the elderly are at risk of
undertreatment because of the underestimation of their sensitivity
to pain, a misconception that they tolerate pain well, and a
reluctance to prescribe adequate doses of opioid analgesics to
older cancer patients.
Pharmacoeconomic Studies
Pharmacoepidemiologic methods are increasingly being used to
evaluate the total costs associated with drug therapy. These studies
include evaluations of the overall effects of drugs on the utilization
of medical services and costs of total medical care. The rates and
costs of beneficial and adverse drug effects may be quantified,
including resource costs such as medication acquisition and
administration, inpatient and outpatient visits, laboratory tests
and procedures, transportation to medical care facilities, and
pain and suffering of the patient. Such methods may be utilized
to compare the cost effectiveness of two or more alternative
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therapies which have different ingredient costs and differ in
efficacy.34 Studies evaluating the additional resource utilization
associated with adverse drug events in hospitalized patients have
assessed the costs of longer periods of hospital stay.35,36 This
subject is discussed in greater detail in Chapter 3.
Quality-of-life Studies
Quality-of-life studies may be conducted to evaluate the influence
of medication use on the patients’ well-being, including such
domains as social, emotional, and physical function. Studies
have evaluated the quality-of-life impact of medications including
treatments for hypertension,37,38 rheumatoid arthritis,39,40 HIV
infection,41 and cancer.42–44 A variety of measurement instruments
have been developed to assess health-related quality of life. These
tools may measure multiple aspects of patient functioning for a
variety of conditions, or may be specific to a particular disease
state, patient population, or function.45 Experience with using
these methods to assess the impact of drug therapy on quality-
of-life in the elderly have been extremely limited and valid
instruments to measure quality-of-life dimensions specifically in
the elderly are few.
Importance of Postmarketing Drug Surveillance
Past tragedies with marketed drugs have emphasized the need
to evaluate drug safety. Possibly the most well-known medication
disaster worldwide occurred in the 1960s shortly after the
marketing of thalidomide, a mild hypnotic drug. A substantial
increase in phocomelia, a birth defect resulting in the absence of
limbs or parts of limbs, was observed, which epidemiologic studies
found to be caused by in utero exposure to thalidomide.46–48 This
and other tragedies49,50 have resulted in the establishment of
national and international committees and bureaus, as well as
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laws and amendments to monitor drug safety, requiring preclinical
testing of drug safety. However, even with the stricter regulation
around the preclinical evaluation of drug safety, a number of
medications have been found to cause serious adverse effects
that have only been detected after marketing.51–54
Because of the limitations of premarketing clinical trials,
pharmacoepidemiologic studies have become increasingly
important in postmarketing drug surveillance (after the time of
drug marketing). At the time a drug is approved for marketing,
generally only a few hundred to a few thousand individuals
have been administered the agent in premarketing clinical trials,
which are primarily designed to assess drug efficacy. This is not
a sufficient number to detect rare adverse events. In addition,
certain patient groups may be excluded from clinical trials, based
on patient gender or age (see Figure 1.1).55 Thus, the experience
Figure 1.1. Percentage of clinical trials of pharmacotherapies employed in the
treatment of acute myocardial infarction that excluded participation on the basis
of patient age. All studies were published between 1960 and 1991. The numbers
in parentheses indicate total number of studies.
(Source: Gurwitz et al., JAMA 1992)
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of drug use in population groups such as the elderly, who are
often more seriously ill than patients included in the pre-
marketing studies, is often unknown at the time of drug
marketing. The effects of long-term use of agents (particularly
those to treat chronic disorders) are generally unknown. Lastly,
evaluation of the patterns and consequences of “typical” use in
the population can only be evaluated once the drug is marketed.
The prescribing patterns and economic impacts of medications
may be difficult to predict before marketing of the drug, and can
only be precisely assessed after marketing.
Principles of Pharmacoepidemiologic Research
The Frequency of Adverse Drug Events
The frequency of the occurrence of an adverse drug event is
the fundamental measurement used in the evaluation of the
distribution and risk factors for such an event. Measures of
frequency commonly used in pharmacoepidemiologic studies are
incidence and prevalence.
Incidence reflects the number of new cases of an adverse event
developing over a specified period of time. Incidence measures
are useful to assess differences in the probability of an adverse
event in different populations and to study etiologic factors
relevant to the occurrence of the event. Cumulative incidence, or
risk, is one measure of incidence, and reflects the number of new
cases of an event developing over a specified time period divided
by the total population at risk of developing the event. Another
measure of incidence is the incidence rate, or incidence density,
which is a useful measure if individuals are followed for varying
lengths of time. The incidence rate reflects the number of new
cases of an event divided by the total sum of the time period at
risk for each individual in the population, measured as person-
time units (e.g., person-years). The person-time for each individual
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is the length of time the individual was a study subject and was
free of the event of interest.
Prevalence reflects the proportion of people at a given point in
time who have experienced an adverse drug event. The numerator
of the prevalence estimate includes all existing cases of an event,
rather than just new cases. The prevalence of an adverse drug
event is a function of the incidence rate and the duration of the
adverse drug event. If the prevalence of an adverse event is low
and the incidence rate is constant over time, the prevalence
equals the incidence rate multiplied by the duration of the
adverse event.
Study Designs
Both experimental and observational designs are used in the
performance of pharmacoepidemiologic studies. In experimental
studies, the investigator allocates subjects to particular treatment
regimens. Observational study designs are more commonly used
in postmarketing surveillance studies. In observational studies,
investigators do not control the allocation of the drug exposure;
they identify and characterize the exposures and events in the
individuals comprising specific populations.
Observational Studies
Case Reports/Case Series
Case reports and case series are descriptions of the experience of
single patients or groups of patients who experience a given
adverse drug event. The governments of many countries operate
systems for collection of spontaneous reports of adverse drug
events. These national systems vary in their organization,
reporting requirements, and management of reports. For most
countries, the reporting of suspected adverse drug events is
DRUGS AND THE OLDER POPULATION 
© Imperial College Press
http://www.worldscibooks.com/medsci/p085.html
PHARMACOEPIDEMIOLOGY AND THE ELDERLY 9
voluntary,56 with the majority received from health care professionals
or pharmaceutical manufacturers.
While these systems are important for the generation of signals
for problems with a medication not detected in pre-marketing
studies, they are often limited by inadequate information to
assess causality. More importantly, the amount of under-reporting
is difficult to estimate, and may be selective, depending on the
time since the drug has been on the market and publication of
reports in the medical literature (see Figure 1.2).56
Ecologic (correlational) Studies
In ecologic studies, the occurrence of an event and of an exposure
are compared over time or in different geographic regions. The
unit of observation is a group of individuals, and the exposure
and event status are not known at the individual level. A major
Figure 1.2. Spontaneous adverse drug reaction reports for seven nonsteroidal anti-
inflammatory drugs in the United Kingdom by year of marketing. Adverse drug
reaction reporting is generally heaviest early in a product’s life cycle. In this case,
adverse drug reaction reporting is five times greater in the second versus the fifth
marketing year.
(Source: Sachs et al., American Journal of Medicine 1986)
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limitation of ecologic studies is the lack of ability to control for
potentially confounding factors. Thus, an observed relationship
between a drug exposure and an adverse event may be due to
another unmeasured or unappreciated factor.
Cross-sectional Studies
Cross-sectional studies determine exposure and event status at
the same point in time. They provide information on the
prevalence of an adverse drug event in specific populations.
However, a major disadvantage of these studies is the difficulty
in determining whether the drug exposure preceded or followed
the occurrence of the event. This study design limitation
compromises the ability to assess whether there is a causal
association between a drug exposure and a potential adverse
drug event.
Case-control Studies
In case-control studies, ‘cases’ who have suffered an adverse
drug event of interest and ‘controls’ who have not suffered an
event are compared with respect to their prior exposure status to
a drug. Case-control studies are relatively quick and inexpensive
to conduct compared to follow-up studies (prospective cohort
studies or clinical trials), and they are useful for the studying of
rare events or events with long latent periods. In addition,
multiple risk factors for a given event may be evaluated. The
main disadvantages of case-control studies relate to potential
biases in the selection of appropriate control groups and
differences in the recall of drug exposures between case and
control patients. Studies based on retrospectively collected data
may be limited by the completeness and validity of the
information available.
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Cohort Studies
In cohort studies, individuals are classified with regard to their
exposure status to a drug and are monitored over time to detect
new cases of the adverse drug event. Cohort studies may be
prospective or retrospective. In prospective study designs, the
events of interest have not occurred at the time the study is
initiated. In retrospective study designs, both the exposures and
events of interest have occurred at the time of initiation of the
study.
Because the individual’s exposure status is determined prior
to the classification of the event status, cohort studies are less
prone to recall bias. Other advantages of cohort studies include
the ability to assess multiple outcomes of a single exposure,
evaluate the effects of rare exposures, and allow direct estimation
of the incidence of an outcome in the exposed and unexposed
populations. However, prospective cohort studies are relatively
expensive, may take an extended period of time to carry out, and
may also require a large number of individuals to evaluate risk
for the occurrence of rare events. Alternatively, retrospective
studies are limited by the completeness and validity of information
available for collection and analysis.
Common Types of Error in Observational Studies
An observed association between an exposure and outcome
should not be accepted as causal. Alternative explanations,
including chance, bias, or confounding, may exist and obscure a
true association, or produce a spurious association. Chance results
from random variation, while bias is a systematic error that
exists as a result of inappropriate study design. For example,
common sources of bias include inappropriate selection of a
control group that is not representative of the source population
in a case-control study (selection bias) and dissimilar quality of
information obtained from the different study groups due to
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differences in procedures to elicit information from individuals
in the different study groups (interviewer bias) or differential
recall of exposure or events among the groups (recall bias).
The third alternative explanation for a noncausal association
is confounding, which occurs when another factor (confounder)
is independently associated with both the exposure and event of
interest and may cause a spurious association or obscure a true
association. In appropriately designed studies, the effect of
confounding may be evaluated and controlled in the design or
analysis of the study findings. One special type of confounding
is confounding by indication. This can occur when the indication
for drug therapy is related to the outcome under study, for
instance, when patients with more severe disease are more likely
to receive the drug than those with less severe disease. Thus, the
true association between the drug and outcome of interest may
be obscured.57 For example, patients at high risk of myocardial
infarction may be more likely to receive anti-hypertensive agents,
such as beta blockers and calcium channel blockers. The
occurrence of myocardial infarction may therefore be increased
in users of these agents compared to nonusers. However, the
association may not be causal in nature, and may reflect the
increased severity or likelihood of the illness under study among
users.58
Experimental Studies
Interventional studies or clinical trials are prospective studies
that involve two or more treatment groups in which the
investigator controls the allocation of the treatment. Clinical trials
are more commonly conducted to evaluate beneficial effects
(efficacy) of preventing or treating disease than are observational
studies. With random assignment of treatment (randomized
clinical trials), the groups are more likely to be comparable
regarding potential confounding factors, including biases in the
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selection of patients for a particular therapy based on perceived
severity of the disease, thus making observed associations more
convincing. However, randomized clinical trials are expensive,
and may be more difficult to design and conduct than
observational studies especially in the geriatric population. Special
effort may be necessary to ensure patient compliance and
continued follow-up. In addition, ethical considerations may
preclude the evaluation of many potential adverse drug events.
Measures of Association
To evaluate the association between drug exposure and a specific
adverse drug event, two important measures of association are
frequently used: the relative risk and the attributable risk.
The relative risk is the ratio of the incidence of an adverse
drug event in persons exposed to a drug to the incidence in
those not exposed to the drug. It may be the ratio of two
cumulative incidences (risk ratio) or the ratio of two incidence
rates (rate ratio). A relative risk greater than 1.0 indicates that the
exposed group has a greater risk for the occurrence of an event
than the unexposed group. A relative risk less than 1.0 indicates
that the exposed group has a lower risk than the unexposed
group. A relative risk of 1.0 indicates that the risks of the event
are identical in the exposed and unexposed groups, suggesting
that the exposure is not associated with the event of interest.
In a case-control study, the incidence of an event in the exposed
and unexposed groups cannot be directly estimated. An estimate
of relative risk, the odds ratio, can be estimated from the data
obtained in case-control studies. The odds ratio is the ratio of the
odds of exposure among cases with the event of interest to the
odds of exposure among the controls without the event.
The attributable risk is the absolute difference between the
incidence in persons exposed to a factor and the incidence in
persons unexposed to a factor. It may be the difference between
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two cumulative incidences (risk difference) or the difference
between two incidence rates (rate difference). The attributable
risk describes the risk of an event in exposed persons that can
be attributable to the exposure. An attributable risk of zero
indicates that the risks of an event are identical in the exposed
and unexposed groups, suggesting that a drug exposure and an
adverse event are unrelated.
Data Sources for Observational Pharmacoepidemiologic
Studies
Ad hoc epidemiologic studies may be performed to evaluate the
use and consequences of drugs in the population. In these studies,
individuals must be identified from appropriate sources and
recruited for study. However, other routinely collected data
sources may be used to perform pharmacoepidemiologic studies.
Automated health care databases are increasingly being used
for pharmacoepidemiologic and health services research. These
databases contain patient-level information from such sources as
Medicaid programs, health maintenance organizations, aggregate
general practitioner systems, governmental health services,
and other health plan databases. Depending on the database,
information on patient demographics, pharmacy records,
outpatient and inpatient diagnoses, outpatient and inpatient
laboratory tests and procedures, as well as enrollment information
may be available. Potential advantages of these databases include
rapid, efficient access to information on drugs and medical services
on large populations with diverse exposures, in turn potentially
resulting in decreased costs for the conduct of the study. In
addition, some sources of bias, such as recall and interviewer
bias, may be minimized. However, the quality and completeness
of the data from these sources should be evaluated. Coding
errors and inadequate documentation by providers may be
problematic. Other potential disadvantages include limited or no
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information on potential confounders or exposures such as alcohol
or tobacco use, inpatient drug exposures, and over-the-counter
drug use. In addition, less severe diseases may not be consistently
documented.
A number of other resources, including registry data, vital
statistics records, and drug utilization data collected by national
and commercial sources, may also facilitate pharmacoepidemiologic
studies. The usefulness of these and other sources of data depends
on the objectives of the proposed study.59
Future Research Directions
Pharmacoepidemiology provides a powerful tool for examining
the impact of drug therapy on the geriatric patient population.
Techniques used to examine drug utilization patterns in the
elderly and adverse effects of specific medications have been
widely utilized with regard to a number of drug classes.
Approaches to fully evaluate the economic impact of drug
therapy in the geriatric population have been less well established.
Similarly, techniques to validly and reliably assess the effects of
drug therapies on the quality-of-life of elderly patients have not
been adequately developed. These highly important areas will
continue to pose the greatest challenges, as well as opportunities,
in geriatirc pharmacoepidemiology.
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